Our Shanghai team specializes in preclinical pharmaceutical development offering a variety of options for study and molecule types, as well as capacity to accommodate fast and flexible study starts. From biologics to Immunotoxicology & Immunology to IND-enabling, our global data approach ensures dependable delivery.
Shanghai Location
Recent Investments & Expansions
Now offering the following enhancements:
- 2X more large animal capacity for fast and flexible study starts
- Options for EU-compliant housing
- Full-service IND-enabling packages for Biologics
- New Immunotoxicology & immunology and cell culture laboratories
- Disease model testing for COPD, IBD, Tumor xenografts, NASH, hepatitis and fibrosis
- Connected scientific and regulatory expertise enabling dual filing in the U.S. and China and large molecule IND-enabling studies
Quick Facts About our Shanghai Facility:
85,000+
Gross Ft2
45+
No. of Study Rooms
5+
No. of PhDs
140+
Total Employment
Site Stats
Capabilities
Specialized Expertise
- Preclinical pharmaceutical development
Capabilities
Qualifications
- AAALAC accredited
- Animal housing compliant with the Guide to the Care and Use of Laboratory Animals, 8th edition
- Good Laboratory Practice (GLP) Certification from the NMPA of the People's Republic of China and the OECD. Inspected by the US FDA
Dose Routes
- Dermal
- IV infusion
- Oral: capsule, gavage
- Parenteral (IM, SC, IV)
Connect
Let's start a conversation
Contact Us